Optimizing antiretroviral therapy for women living with HIV

Current Opinion in Infectious Diseases

Volumn 27, Issue 1, 2014, Pages 46-52

  Greig, Julia M ^a   Anderson, Jane ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

antiretroviral therapy; HIV; women

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

BODY MASS; CLINICAL TRIAL (TOPIC); CONDOM; CONTRACEPTION; DRUG EFFECT; DRUG METABOLISM; EARLY MENOPAUSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID STORAGE; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; NEURAL TUBE DEFECT; OSTEOPOROSIS; POLYPHARMACY; PREGNANCY; REVIEW; VERTICAL TRANSMISSION; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; SEX FACTORS;

EID: 84891830312     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000033     Document Type: Review

References (55)

1. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2012. http://www.ecdc.europa.eu/en/publications/ Publications/Annual-Epidemiological-Report-2012.pdf. [Accessed 27 October 2013]
2. May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011; 343:; d61016.
3. WHO/UNAIDS policy statement. http://www.who.int/hiv/pub/advocacy/en/ policy%20statement-gwh.pdf. [Accessed 21 October 2013]
4. Stengaard AR, Lazarus JV, Donoghoe MC, et al. Access to highly active antiretroviral therapy (HAART) for women and children in the WHO European Region 2002-2006. AIDS Care 2009; 21:893-902.
5. Del Amo J, Likatavic? ius G, Pé rez-Cachafeiro S, et al. The epidemiology of HIV and AIDS reports in migrants in the 27 European Union countries, Norway and Iceland: 1999-2006. Eur J Public Health 2011; 21:620-626.
6. Thomas F, Aggleton P, Anderson J. 'If I cannot access services, then there is no reason for me to test': the impacts of health service charges on HIV testing and treatment amongst migrants in England. AIDS Care 2010; 22:526-531.
7. Doyal L. Challenges in researching life with HIV/AIDS: an intersectional analysis of black African migrants in London. Cult Health Sex 2009; 11:173-188.
8. Barber TJ, Geretti AM, Anderson J, et al. Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther 2011; 16:805-814.
9. Murri R, Lepri AC, Phillips AN, et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N. A Study. J Acquir Immune Defic Syndr 2003; 34:184-190. (Pubitemid 37248915)
10. Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32:452-461. (Pubitemid 36363161)
11. Thorsteinsson K, Ladelund S, Jensen-Fangel S, et al. Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study. BMC Infect Dis 2012; 12:293.
12. Wandeler G, Keiser O, Hirschel B, et al. A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS One 2011; 6:e27903.
13. Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavirritonavir therapy: a single-group trial. Ann Intern Med 2010; 153:349-357.
14. MartorellC,MayerCA,RiberaE, et al.Week96safetyandefficacybygenderand race subgroupsin treatment-na?̈ve HIV-1-infected patients in thephase IIIECHO and THRIVE trials [abstract]. In: Annual Meeting of the Infectious Diseases Society of America; 20-23 October 2011; Boston, MA. Abstr. no. 404.
15. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS 2013; 27:939-950.
16. Squires KE, Johnson M, Yang R, et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother 2011; 66:363-370.
17. Smith KY, Tierney C, Daar E, et al. Association of race/ethnicity and sex with outcomes in ACTG A5202 [abstract]. In: 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011); 27 February-2 March 2011; Boston, MA. Abstr. no. 404.
18. Soon GG, Min M, Struble KA, et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS 2012; 26:444-453.
19. Kile DA, MaWhinney S, Aquilante CL, et al. A population pharmacokineticpharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses 2012; 28:1227-1234.
20. von Hentig N, Babacan E, Lennemann T, et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother 2008; 62:579-582.
21. Boffito M, Else L, Back D, et al. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir Ther 2008; 13:901-907.
22. Kakuda T, Sekar V, Vis P, et al. Pharmacokinetics and pharmacodynamics of darunavir and etravirine in HIV-1-infected, treatment-experienced patients in the gender, race, and clinical experience (GRACE) Trial. AIDS Res Treat 2012; 2012:186987.
23. Umeh OC, Currier JS, Park JG, et al. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol 2011; 51:1665-1673.
24. Currier JS, Martorell C, Osiyemi O, et al. Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS 2011; 25:333-340.
25. Regazzi M, Villani P, Seminari E, et al. Sex differences in nevirapine disposition in HIV-infected patients. AIDS 2003; 17:2399-2400. (Pubitemid 38147029)
26. Marinho AT, Rodrigues PM, Caixas U, et al. Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions. J Antimicrob Chemother 2013. [Epub ahead of print]
27. Antinori A, Baldini F, Girardi E, et al. Female sex and the use of antiallergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001; 15:1579-1581. (Pubitemid 32744607)
28. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32:124-129. (Pubitemid 32150957)
29. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV nonnucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006; 61:148-154. (Pubitemid 43382608)
30. Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170:57-65.
31. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol 1998; 38:1003-1009. (Pubitemid 28524446)
32. Hodder S, Arasteh K, De Wet J, et al. Effect of gender and race on the week 48 findings in treatment-na?̈ve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med 2012; 13:406-415.
33. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38. (Pubitemid 47017466)
34. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48. (Pubitemid 47017467)
35. Osler M, Stead D, et al. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med 2010; 11:121-129.
36. & Rower JE, Meditz A, Gardner EM, et al. Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrob Agents Chemother 2012; 56:3011-3019.
37. Aziz M, Smith KY. Treating women with HIV: is it different than treating men? Curr HIV/AIDS Rep 2012; 9:171-178.
38. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008; 83:293-299.
39. Arab-Alameddine M, Fayet-Mello A, Lubomirov R, et al. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agents Chemother 2012; 56:2959-2966.
40. Squires KE, Bekker LG, Eron JJ, et al. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. AIDS Res Hum Retroviruses 2013; 29:859-870.
41. European Centre for Disease Prevention and Control. HIV/AIDS surveillance in Europe 2010. http://ecdc.europa.eu/en/publications/Publications/111129-SUR- Annual-HIV-Report.pdf. [Accessed 21 October 2013]
42. Robinson JA, Jamshidi R, Burke AE. Contraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapy. Infect Dis Obstet Gynecol 2012; 2012:890160.
43. Crauwels HM, van Heeswijk RP, Buelens A, et al. Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers. Int J Clin Pharmacol Ther 2013. [Epub ahead of print]
44. Schöller-Gyü re M, Kakuda TN, Woodfall B, et al. Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. Contraception 2009; 80:44-52.
45. Watts DH, Park JG, Cohn SE, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 2008; 77:84-90.
46. Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007; 81:222-227. (Pubitemid 46174819)
47. Nanda K, Amaral E, Hays M, et al. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril 2008; 90:965-971.
48. Lakhi N, Govind A. Implanon failure in patients on antiretroviral medication: the importance of disclosure. J Family Plan Reprod Healthcare2010; 36:181-182.
49. Cliffe S, Townsend CL, Cortina-Borja M, Newell ML. Fertility intentions of HIVinfected women in the United Kingdom. AIDS Care 2011; 23:1093-1101.
50. Taylor GP, Clayden P, Dhar J, et al. British HIV Association guidelines for the management of HIV infection in pregnant women 2012. HIV Med 2012; 13 (S2):87-157.
51. Sibiude J, Mandelbrot L, Blanche S, et al. Birth defects and ART in the French Perinatal Cohort, a prospective exhaustive study among 13 124 live births from 1994 to 2010 [abstract]. In: 19th CROI; 3-6 March 2013; Atlanta, GA. Abstr. no. 81.
52. Luther VP, Wilkin AM. HIV infection in older adults. Clin Geriatr Med 2007; 23:567-583. (Pubitemid 47042341)
53. Althoff KN, Justice AC, Gange SJ, et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010; 24:2469-2479.
54. Jacobson DL, Knox T, Spiegelman D, et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005; 40:1837-1845. (Pubitemid 40799956)
55. Onen NF, Overton ET, Seyfried W, et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010; 11:100-109.